PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
226.57%
Some net income increase while VET is negative at -19.69%. John Neff would see a short-term edge over the struggling competitor.
-48.89%
Negative yoy D&A while VET is 6.98%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
1240.68%
Well above VET's 188.71% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
98.30%
Working capital change of 98.30% while VET is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might affect near-term cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Growth of 100.00% while VET is zero at 0.00%. Bruce Berkowitz would see a difference in minor WC usage that might affect short-term cash flow if large.
-23.02%
Both negative yoy, with VET at -88.37%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
21.05%
Some CFO growth while VET is negative at -26.60%. John Neff would note a short-term liquidity lead over the competitor.
18.58%
CapEx growth of 18.58% while VET is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
-155.78%
Negative yoy acquisition while VET stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
168.74%
Purchases growth of 168.74% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
-162.53%
We reduce yoy sales while VET is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
-157.56%
We reduce yoy other investing while VET is 162.40%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
365.10%
We have mild expansions while VET is negative at -26.85%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
17.77%
Debt repayment growth of 17.77% while VET is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
227.31%
Stock issuance far above VET's 264.41%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
-186831.83%
We cut yoy buybacks while VET is 0.00%. Joel Greenblatt would question if competitor is gaining a per-share edge unless expansions justify holding cash here.